Type 1 diabetes mellitus (T1DM) is an endocrine disorder in which pancreatic β cells stop
producing insulin, typically due to autoimmune destruction. This results in hyperglycemia …

Autoimmune diseases (ADs) are characterized by the production of autoreactive
lymphocytes, immune responses to self-antigens, and inflammation in related tissues and …

Objective To better define the rare adverse event (AE) of diabetes mellitus associated with
immune checkpoint inhibitors (ICIs). Design and methods We report the case of a lung …

The emergence and continuous development of immune checkpoint inhibitors (ICIs) therapy
brings a revolution in cancer therapy history, but the major hurdle associated with their …

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but are associated
with significant autoimmune endocrinopathies that pose both diagnostic and treatment …

Immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 (PD-1) and its ligand
PD-L1 and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibodies, are …

In recent years, immunotherapy has been widely used to treat patients with malignant
tumors. While immune checkpoint inhibitors (ICIs) significantly improve the prognosis of …

Abstract PD‐1 and CTLA‐4 can play an important role in addressing the issue of
autoimmune diseases. PD‐1 is a transmembrane glycoprotein expressed on T, B, and …

Background Observational studies have indicated associations between type 2 diabetes
mellitus (T2DM) and both colorectal cancer (CRC) and inflammatory bowel disease (IBD) …

The emergence of immune checkpoint inhibitors in the arsenal of cancer immunotherapy
was a breakthrough which provided hope to many cancer patients. However, not long has …